Boehringer Ingelheim entered a multi-product preclinical deal with Sino Biopharmaceutical for six asset options spanning antibody-drug conjugates and T cell engagers. Boehringer will pay $358 million up front for the option rights, with the agreement structured around major milestones totaling $7 billion. The partnership reflects the ongoing flow of modality assets from China-originating pipelines into Western portfolios, particularly in ADC and TCE categories. Boehringer’s approach focuses on taking options on preclinical programs rather than immediate full development ownership. With China-originated dealmaking expanding, the transaction reinforces competition for differentiated constructs and target classes, while also highlighting the continued investor and sponsor appetite for early-stage access. For biotech leadership teams, the terms underline how ADC/TCE platform investments remain central to deal strategy and how milestone-heavy structures are being used to manage development risk.